Compare · DXCM vs GNMK
DXCM vs GNMK
Side-by-side comparison of DexCom Inc. (DXCM) and GenMark Diagnostics, Inc. (GNMK): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and GNMK operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM carries a market cap of $40.07B.
- DXCM has hit the wire 4 times in the past 4 weeks while GNMK has been quiet.
- DXCM has more recent analyst coverage (25 ratings vs 0 for GNMK).
- Company
- DexCom Inc.
- GenMark Diagnostics, Inc.
- Price
- $61.55-1.84%
- -
- Market cap
- $40.07B
- -
- 1M return
- -7.89%
- -
- 1Y return
- -13.51%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- 2010
- News (4w)
- 4
- 0
- Recent ratings
- 25
- 0
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest DXCM
- SEC Form 4 filed by Brown Michael Jon
- SEC Form DEFA14A filed by DexCom Inc.
- SEC Form DEF 14A filed by DexCom Inc.
- SEC Form 144 filed by DexCom Inc.
- Dexcom Schedules First Quarter 2026 Earnings Release and Conference Call for April 30, 2026 at 4:30 p.m. Eastern Time
- Amendment: SEC Form SCHEDULE 13G/A filed by DexCom Inc.
- Dexcom upgraded by Evercore ISI with a new price target
- SEC Form 4 filed by Brown Michael Jon
- Dexcom Showcases Breakthrough Outcomes for People With Type 2 Diabetes and Product Roadmap at ATTD 2026
- EVP, Chief Financal Officer Sylvain Jereme M was granted 48,774 shares and covered exercise/tax liability with 18,950 shares, increasing direct ownership by 24% to 153,292 units (SEC Form 4)
Latest GNMK
- Gene Panel Market size worth $ 8.22 Million, Globally, by 2028 at 21.36% CAGR: Verified Market Research®
- SEC Form SC 13G/A filed by GenMark Diagnostics, Inc. (Amendment)
- SEC Form 15-12B filed by GenMark Diagnostics, Inc.
- SEC Form EFFECT filed by GenMark Diagnostics, Inc.
- SEC Form S-8 POS filed by GenMark Diagnostics, Inc.
- SEC Form S-8 POS filed by GenMark Diagnostics, Inc.
- SEC Form S-8 POS filed by GenMark Diagnostics, Inc.
- SEC Form S-8 POS filed by GenMark Diagnostics, Inc.
- SEC Form S-8 POS filed by GenMark Diagnostics, Inc.
- SEC Form S-8 POS filed by GenMark Diagnostics, Inc.